Summary
45 / 100 · Bulios Score
What speaks for it
- It earns 806 USD a year on every 100 USD of invested capital.
- The share price is below the Bulios Fair Price.
What to watch
- The company made a loss over the last 12 months.
- Operating profit does not even cover the interest on its debt.
- Revenue grew by only 1.6% a year over the last 3 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 3.6% a year over 5 years. Over the last 3 years it grew by 1.6% a year. For the next fiscal year analysts expect revenue to grow by 1.4%.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 48 USD
- Research and development 5.7 USD
- Sales and administration 8.5 USD
- Taxes and other 38 USD
- Net profit 0.8 USD
Net profit, industry median (Medical - Devices) 6.9 USD
Out of every 100 USD of revenue, 0.8 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt has no debt. The debt score is low because of the debt-to-equity ratio (1.9x).
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 12
- Hold 12
- Sell 4
Today's price within the analysts' price targets
The average target of $18 is 51% above today's price. 43% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Codman Specialty Surgical 73%
- Tissue Technologies 27%
By region
- UNITED STATES 74%
- Asia Pacific 12%
- Europe 9.9%
- Rest Of The World 4.8%
Codman Specialty Surgical brings in 73% of revenue.
Segments in detail